Цилостазол – антиагрегант з великими перспективами
DOI:
https://doi.org/10.37987/1997-9894.2018.2(218).195627Ключові слова:
серцево-судинні захворювання, антиагрегантні препарати, вторинна профілактика, цилостазолАнотація
На сьогодні у лікуванні серцево-судинних захворювань широко застосовуються антиагрегантні препарати. У статті на основі численних клінічних досліджень показана ефективність інгібітора агрегації тромбоцитів цилостазолу, який, за деякими своїми властивостями, переважає за ефективністю ацетилсаліцилову кислоту.
Унікальність цилостазолу в тому, що це єдиний препарат із доведеною ефективністю при лікуванні атеросклерозу периферійних артерій, переміжної кульгавості. Грунтуючись на результатах ряду рандомізованих досліджень і даних мета-аналізів наведені дані щодо його ефективності при вторинній профілактиці порушень мозкового кровотоку – інсульту і транзиторних ішемічних атак, при проведенні ендоваскулярних втручань, в тому числі стентування периферійних, брахіоцефальних, коронарних артерій.
Безпечність застосування цилостазолу доведена результатами цілого ряду клінічних досліджень.
Посилання
Архипов В. В. Клиническая фармакология ингибиторов фосфодиэстеразы / В. В. Архипов // Практическая пульмонология. – 2014. – No 3. – С. 35–41.
Cilostazol reduced in flam matory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients / N. K. Agrawal, R. Maiti, D. Dash, B. L. Pandey // Pharmacol. Res. – 2007. – Vol. 56 (2). – P. 118–123.
Asal N. J. Effect of cilostazol in treating diabetes-associated microvascular complications / N. J. Asal, R. A. Wojciak // Endocrine. – 2017. – Vol. 56 (2). – P. 240–244.
Beebe H. G. A new pharmacological treatment for intermittent claudication: result of a randomized multicenter trial / H. G. Beebe, D. L. Dawson, B. S. Cutler // Frch. Intern. Med. – 1999. – Vol. 159 (17). – P. 2041–2050.
Cost-effectiveness analysis of cilostazol vs naftidrofuryl and pentoxifilline for the treatment of intermittent claudication in Spain / M. Brossa, C. Garcia-Cases, L. Clerch [et al.] // Angiologia. – 2011. – Vol. 63 (3). – P. 103–107.
Effect of cilostazol on the progression of carotid intima-media thickness: A metaanalysis of randomized controlled trials / Deng-feng Geng, Jing Deng, Jing-feng Wanga [et al.] // Atherosclerosis. – 2012. – Vol. 220, Nо. 1. – P. 177–183.
Derry S. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis / S. Derry, Y. K. Loke // BMJ. – 2000. – Vol. 321. – P. 1183–1187.
Friedland S. N. Meta-analysis of randomized contolled trrails on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention / S. N. Friedland, M. J. Eisenberg, A. Shimony // Am. J. Cardiol. – 2012. – Vol. 109 (10). – P. 1397–1404.
Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke prone spontaneously hypertensive rats / Y. Fujita, J. X. Lin, R. Takahashi, H. Tomimoto // Brain Res. – 2008. – Vol. 1203. – P. 170–176.
AHA/ACC Guadeline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines / M. D. Gerhard-Herman, Y. L. Gornik, C. Barrett [et al.] // J. Amer. Cardiol. – 2017. – No 21, Vol. 69 (11). – P. 1465–1508.
Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction / F. Gotoh, H. Tohgi, S. Hirai [et al.] // Stroke Cerebrovasc. Dis. – 2000. – Vol. 9 (4). – P. 147–157.
Gruberg L. CREST: Cilostazol for Restenosis Trial / L. Gruberg – URL: www.Theheart.org. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP / protein kinase A and phosphatidylinositol 3-kinase / Akt-dependent mechanism / A. Hashimoto, G. Miyakoda, Y. Hirose, T. Mori // Atherosclerosis. – 2006. – Vol. 189 (2). – P. 350–357.
Hiatt W. R. The US experience with cilostazol in treating intermittent claudication / W. R. Hiatt // Atheroscler Suppl. – 2006. – Vol. 6. – P. 21–31.
Cilostazol Stimulates Revascularisation in Response to Ischaemia via an tNOS-Dependent Mechanism / A. Horia, R. Shibatab, K. Morisakia [et al.] // Eur. J. Vasc. Endovasc. Surg. – 2012. – Vol. 43, Nо. 1. – P. 62–65.
The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression. Metabolism / Hyung Jun Kima, Jae Hoon Moonb, Hyun Min Kima [et al.] // Available online. – 2013. – 17 October.
Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells / T. Igawa, T. Tani, T. Chijiwa [et al.] // Thromb. Res. – 1990. – Vol. 57. – P. 617–623.
Beneficial effects of cilostazol in a patient with recurrent ventricular fibrillation associated with early repolarization syndrome / K. Iguchi, T. Noda, S. Kamakura, W. Shimizu // Heart Rhythm. – 2013. – Vol. 10, Nо. 4. – P. 604–606.
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteallesions in the Sufficient Treatment of Periferal Intervention by Cilostazol study / O. Iida, H. Yokoi, Y. Soga [et al.] // Circulation. – 2013. – Vol. 127, Nо. 23. – P. 2307–2315.
Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study / Y. Ikeda, M. Kikuchi, H. Murakami [et al.] // Arzneimittelforschung. – 1987. – Vol. 37 (5). – P. 563–566.
Ikeda Y. Cilostazol / Y. Ikeda, T. Sudo, Y. Kimura // Platelets ; Michelson AD (ed) – Amsterdam : Elsevier, 2006. – P.1181–1191.
Phosphodiesterase-III ingibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA / M Іshiguro, K. Mishiro, H. Chen [et al.] // PLoS One. – 2010. – No 5. – Р. е15178
Suppression of neointimal hyperplasia by external application of cilostazol-eluting film at anastomotic sites in a canine model / T. Kagatani, K. Oda, S. Kawatsu [et al.] // Japan J. Surg. – 2010. – Vol. 39, Nо. 4. – P. 162–171.
Kim K. Y. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells / K. Y. Kim, H. K. Shin, K. W. Yjng // J. Pharmacol. Exp. Ther. – 2002. – Vol. 300. – P. 709–715.
Effect of cilostazol on platelet aggregation and experimental thrombosis / H. Kimura, T. Tani, T. Kanbe, K. Watanabe // Arzneimittelforschung. – 1985. – Vol. 35. – P. 1144–1149.
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis / S. U. Kwon, Y. J. Cho, J. S. Koo [et al.] // Stroke. – 2005. – Vol. 36. – P. 782–786.
Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6 / T. M. Lee, S. F. Su, J. J. Hwang [et al.] // Atherosclerosis. – 2001. – Vol. 158 (2). – P. 471–476.
Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes / N. J. Leeper, A. Bauer-Mehren, S. V. Lyer [et al.] // PLoS One. – 2013. – Vol. 8 (5). – P. e63499.
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation / S. Manickavasagam, Y. Ye, Y. Lin [et al.] // Cardiovascular Drugs Ther. – 2007. – Vol. 21. – P. 321–330.
On behalf of the TASC II Working group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) / L. Norgren, W. R. Hiatt, J. A. Dormandy [et al.] // J. Vasc. Surg. – 2007. – Suppl. 1. – P. 5–67.
Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers / K. Oida, K. Ebata, H. Kanehara [et al.] // J. Atheroscler. Thromb. – 2003. – Vol. 1. – P. 93–98.
Pratt C. M. Analysis of the cilostazol safety database / C. M. Pratt // Am. J. Cardiol. – 2001. – Vol. 87. – P. 28D–33D.
Effect of cilostazin on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials / J. G. Regensteiner, J. E. Ware Jr., W. J. McCarthy [et al.] // J. Am. Geriatr. Soc. – 2002. – Vol. 50 (12). – P. 1939–1946.
Resnick K. A. Effects of cilostazol on arterial wound healing: a retrospective analysis / K. A. Resnick, I. L. Gordon // Ann. Vasc. Surg. – 2014. – Vol. 28, Nо. 6. – P. 1513–1521.
Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan / C. Sakamoto, K. Sugano, S. Ota [et al.] // Eur. J. Clin. Pharmacol. – 2006. – Vol. 62. – P. 765–772.
A randomized, multicentre double-blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients woth vasospastic angina / E. S. Shin, J. H. Lee, S. Y. Yoo [et al.] // Heart DOI: 10.1136/heartjnl-2014-305986.
Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomized non-inferiority trial / Y. Shinohara, Y. Katayama, S. Uchiyama [et al.] // The Lancet Neurology. – 2010. – Vol. 8,Issue 10. – P. 959–968.
Soga Y. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia / Y. Soga, O. Iida, D. Kawasaki // Eur. J. Vasc. Endovasc. Sur. – 2012. – Vol. 44, Nо. 6. – P. 577–581.
Effects of cilostazol against the progression of carotid AMT in symptomatic ischemic stroke patients / Sung Hyuk Heo, Ji Sung Lee, Beom Joon Kim [et al.] // J. Neurol. – 2013. – Vol. 260, Nо. 1. – P. 122–130.
Takigawa T. Cilostazol reduced restenosis after carotid artery stenting / T. Takigawa, Y. Matsumaru, M. Hayakawa // J. Vasc. Surg. – 2010. – Vol. 51, Nо. 1. – P. 51–56.
Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle / T. Tanaka, T. Ishikawa, M. Hagiwara [et al.] // Pharmacology. – 1988. – Vol. 36. – P. 313–320.
ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery disease: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Disease of the European Society of Cardiology (ECS) / M. Tendera, V. Abouans, M. L. Bartelink [et al.] // Eur. Heart J. – 2011. – Vol. 32. – P. 2851–2906.
Cilostazol inhibits the redistribution of the action cytoskeleton and junction al proteins on the blood-brain under hypoxia/reoxygenation / H. Torii, H. Kubota, H. Ishihara, M. Suzuki // Pharmacol. Res. – 2007. – Vol. 55. – P. 104–110.
Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2 / S. Uchiyama, Y. Shinohara, Y. Katahashi [et al.] // Cerebrovasc Dis. – 2014. – Vol. 37. – P. 296–303.
